Press release in respect of unaudited ( Standalone and Consolidated) Financial Results for the quarter ended 30 June 2026

Date: 12 August 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear Sir / Ma’am, Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Sub: Press release in respect of unaudited (standalone and consolidated) financial results of the Company for quarter ended 30 June 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter ended 30 June 2026. Further, details as required to be disclosed as per BSE’s Circular No. 20230714-34 dated 14 July 2023, and NSE’s Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under: Date of occurrence of Event/Information: 12 August 2026 Time of occurrence of Event/Information: 04:30 P.M. (IST) This may please be informed to all the concerned. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Encl.: as above Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 SURAKSHA DIAGNOSTIC LIMITED Suraksha Diagnostics Delivers Strong Q1 FY27 Performance PAT grew by 40% year-on-year and EBITDA grew by 28% year-on-year Kolkata, 12th Aug 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announceditsunauditedfinancialresultsforthequarterended30thJune2026. Q1 FY27 Financial Performance Snapshot (Y-o-Y) Total Income EBITDA Profit After Tax EPS ₹ 887 million ₹ 315 million ₹ 128 million ₹ 2.5 +21% +28% +40% ₹0.70 Key Financial Highlights Particulars Q1 FY27 Q1 FY26 Y-o-Y FY26 FY25 Y-o-Y Total Income (₹ million) 887.33 734.92 20.7% 3135.78 2559.39 22.5% EBTIDA (₹ million) 315.30 246.56 27.9% 985.58 850.88 15.8% EBTIDA Margin (%) 36.0% 34.0% 31.8% 33.8% PAT (₹ million) 128.45 91.75 40.0% 314.04 309.78 1.4% PAT Margin (%) 14.7% 12.6% 10.1% 12.3% Key Operational Highlights Particulars Q1 FY27 Q1 FY26 Y-o-Y FY26 FY25 Y-o-Y Total tests (# million) 2.10 1.92 8.9% 8.16 6.68 22.0% Total Patients (# million) 0.38 0.33 12.1% 1.37 1.19 14.9% Tests per patient (#) 5.56 5.72 -2.8% 5.95 5.60 6.2% Average Revenue per test (₹) 418 377 10.6% 381 377 0.9% Average Revenue per patient (₹) 2,321 2,101 10.5% 2,264 2,113 7.1% SURAKSHA DIAGNOSTIC LIMITED CommentingontheresultsMrs.RituMittal,JointManagingDirector&CEOsaid,- “Suraksha has started FY27 on a strong note, delivering healthy growth across both volumes and realisations. Revenue grew 21% YoY in Q1 FY27, with EBITDA increasing 28% and PAT growing 40%, supported by an improvementinEBITDAmarginto36.0%. The quarter witnessed healthy growth in both patient and test volumes, reflecting continued strength in underlying consumer demand. This was complemented by healthy realisation growth, supporting a strong overallperformanceduringthequarter. We continued to expand our network during the quarter, commissioning one hub and three spoke centres, in linewithourstrategyofbuildingclustersandprogressivelyincreasingdensityaroundthem.Weremainfocused on strengthening our presence across existing and new markets while maintaining a disciplined approach to expansion. Suraksha Genomics continued itsstronggrowthtrajectory, delivering revenuegrowthof 136% YoYin Q1 FY27, marking the fifth consecutive quarter of sequential growth. While still at an early stage, we believe genomics hasthepotentialtoemergeasanincreasinglymeaningfulcontributortoourbusinessoverthecomingyears.” AboutSurakshaDiagnosticLimited: SurakshaDiagnosticLimitedisaleadingproviderofintegratedsolutionsinpathologyandradiologytesting,aswellasmedical consultationservices,offeringaseamlessexperiencetocustomersthroughanextensiveoperationalnetwork.Thecompany isthelargestintegrateddiagnosticchainwithapresenceinthestatesofWestBengal,BiharandAssam. Thecompany’scentralreferencelaboratoryisaccreditedbytheCollegeofAmericanPathologists,whilethe4laboratorieshold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centresareaccreditedbytheNationalAccreditationBoardforHospitals&HealthcareProviders(NABH). Company: Suraksha Diagnostic Limited Investor Relations: MUFG Intime India Private Limited Name: Mr. Omkar Bagwe Email: investors@surakshanet.com Email: omkar.bagwe@in.mpms.mufg.com Name: Sumeet Khaitan CIN: L85110WB2005PLC102265 Email:Sumeet.khaitan@in.mpms.mufg.com Website: https://www.surakshanet.com/ Meeting Request Link –Click Here SafeHarbor Any forward-looking statementsabout expected future events, financialand operating resultsof the Companyare based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations includea downtrend in the industry, globalor domesticor both, significant changes in politicaland economic environmentinIndiaorkeymarketsabroad,taxlaws,litigation,labourrelations,exchangeratefluctuations,technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertakeanyobligationtoupdateforward-lookingstatementstoreflecteventsorcircumstancesafterthedatethereof.